Adult Acute Lymphoblastic Leukemia (ALL)
CONCLUSION: The polymorphism of MTHFR C677T/A1298C may not be an important indicator for the accurate detection of side effects of chemotherapy after using MTX. More relative research is needed.
PMID: 30024839 [PubMed – as supplied by publisher]
Conditions: Vincristine Induced Neurotoxicity; Acute Lymphoblastic Leukaemia Interventions: Drug: Injection Mecobalamin; Drug: Tablet Pyridoxine hydrochlorid; Drug: Normal saline; Drug: Oral Placebo Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Recruiting
Authors: Corella Aznar EG, Ayerza Casas A, Carboné Bañeres A, Calvo Escribano MÁC, Labarta Aizpún JI, Samper Villagrasa P
BACKGROUND: Survival of childhood acute lymphoblastic leukaemia involves an increasing risk of long-term morbidities. Due to the impact of cancer treatment and comorbidities, AL survivors may experience a decrease in their health-related quality of life.
OBJECTIVE: We aimed to describe the long-term comorbidities, related quality of life and their development predictors in these survivors.
METHODS: cross-sectional study of 54 survivors aged ≥18 and…
Conclusions: SLC7A7 plays a significant role in the pathogenesis of T-cell acute lymphoblastic leukemia.Cell Physiol Biochem 2018;48:731 –740
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma, Published online: 19 July 2018; doi:10.1038/s41375-018-0213-yAcute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma
Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)–type primary th…
ConclusionOMF ALL/LBL is rare, but its microscopic features and immunohistochemical profiles CD3+or CD79 a+/CD10+/CD34+variable/CD99+/TdT+ contribute to the correct diagnosis.
Publication date: October 2018Source: Biocatalysis and Agricultural Biotechnology, Volume 16Author(s): Marília Crivelari da Cunha, Laura Carvalho Silva, Hélia Harumi Sato, Ruann Janser Soares de CastroAbstractMicrobial L-asparaginase have been used as a therapeutic agent in the treatment of acute lymphoblastic leukemia and Hodgkin’s disease. In addition to clinical use, L-asparaginases have been used in foods to reduce the formation of acrylamide. L- asparaginase production is carried out mainly by submerged fermentation (SmF). However, solid-state fermentation (SSF) offers potential benefits compared with su…
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic leukemia (ALL), discusses Anthony Moorman, PhD, of Newcastle Univer…
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer…